PA
RDHL

Parallel Advisors’s Redhill Biopharma RDHL Stock Holding History

Parallel Advisors’s Portfolio RDHL Stock Details RDHL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Hold
0
– – – 3252
2021
Q3 		– Hold
0
– – – 3236
2020
Q4 		– Hold
0
– -$2K – 2691
2020
Q3 		– Hold
0
– – – 2331
2017
Q4 		– Sell
-1
Closed -$7K – 2127
2017
Q3 		$7K Buy
+1
New +$8.89K ﹤0.01% 1441

Other funds holding RDHL

DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
II
Ibex Investors Denver, Colorado $152M AUM 19.17% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CAM
Claret Asset Management Montreal, Quebec, Canada $837M AUM 25.51% 1-Year Est. Return
AA
Ancora Advisors Cleveland, Ohio $4.7B AUM 19.05% 1-Year Est. Return

Parallel Advisors's RDHL Position: Q4 2021 in Review

Parallel Advisors held its Redhill Biopharma (RDHL) position steady in Q4 2021 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #3252.

Parallel Advisors first reported a position in RDHL in Q3 2017 and has held it in 1 quarter since. The position peaked at $7K in Q3 2017. 51 funds tracked by Wall St. Rank hold RDHL as of Q4 2021.

  • Parallel Advisors held 0 shares of Redhill Biopharma worth $0 as of Q4 2021.
  • Parallel Advisors left its Redhill Biopharma share count unchanged in Q4 2021.
  • Redhill Biopharma made up ﹤0.01% of Parallel Advisors's portfolio in Q4 2021, its #3252 holding.
  • Parallel Advisors first reported a position in Redhill Biopharma in Q3 2017 and has held it in 1 quarter since.
  • Parallel Advisors's Redhill Biopharma position peaked at $7K in Q3 2017.
  • 51 funds tracked by Wall St. Rank held Redhill Biopharma as of Q4 2021.

Based on Parallel Advisors's 13F filing for Q4 2021, filed 20 Jan 2022.